The efficacy of botulinum toxin in neuropathic pain: a systematic review.
Br J Pain
; 18(5): 388-402, 2024 Oct.
Article
em En
| MEDLINE
| ID: mdl-39372103
ABSTRACT
Introduction:
Neuropathic pain (NP) is characterised as a lesion or disease directly affecting the somatosensory system. This study aims to analyse the efficacy of botulinum toxin type A (BT-A) in the treatment of neuropathic pain.Methods:
This systematic literature review, guided by PRISMA, applied the PICO strategy with the following criteria (P = patients with neuropathic pain, I = botulinum toxin, C = placebo or active drug, and O = pain relief).Results:
Fourteen articles, all randomised controlled trials with a placebo control, were included in the review. A total of 645 patients were randomised, with 353 patients receiving treatment with botulinum toxin type A in doses ranging from 25U to 400U. The evaluated studies addressed trigeminal neuralgia, diabetic polyneuropathy, post-herpetic neuralgia, spinal cord injury, phantom limb pain, and peripheral neuropathic pain after trauma or surgery.Conclusion:
BT-A has emerged as a promising treatment for various origins of neuropathic pain. Therefore, future studies should adopt stricter criteria regarding dosage and routes of administration to ensure effective and consistent BT-A application.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Idioma:
En
Revista:
Br J Pain
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
Brasil
País de publicação:
Reino Unido